AR082428A1 - Uso de un compuesto agonista de ep4 para preparar una composicion farmaceutica util para tratar una imperfeccion de la piel y metodos para reparar la piel relacionados - Google Patents

Uso de un compuesto agonista de ep4 para preparar una composicion farmaceutica util para tratar una imperfeccion de la piel y metodos para reparar la piel relacionados

Info

Publication number
AR082428A1
AR082428A1 ARP110102761A ARP110102761A AR082428A1 AR 082428 A1 AR082428 A1 AR 082428A1 AR P110102761 A ARP110102761 A AR P110102761A AR P110102761 A ARP110102761 A AR P110102761A AR 082428 A1 AR082428 A1 AR 082428A1
Authority
AR
Argentina
Prior art keywords
skin
prepare
pharmaceutical composition
imperfection
methods
Prior art date
Application number
ARP110102761A
Other languages
English (en)
Spanish (es)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR082428A1 publication Critical patent/AR082428A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
ARP110102761A 2010-07-30 2011-07-29 Uso de un compuesto agonista de ep4 para preparar una composicion farmaceutica util para tratar una imperfeccion de la piel y metodos para reparar la piel relacionados AR082428A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36923210P 2010-07-30 2010-07-30
US41911510P 2010-12-02 2010-12-02

Publications (1)

Publication Number Publication Date
AR082428A1 true AR082428A1 (es) 2012-12-05

Family

ID=44543791

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102761A AR082428A1 (es) 2010-07-30 2011-07-29 Uso de un compuesto agonista de ep4 para preparar una composicion farmaceutica util para tratar una imperfeccion de la piel y metodos para reparar la piel relacionados

Country Status (18)

Country Link
US (1) US20120136011A1 (enExample)
EP (1) EP2598140B1 (enExample)
JP (1) JP2013536183A (enExample)
KR (1) KR20130130694A (enExample)
CN (1) CN103068382A (enExample)
AR (1) AR082428A1 (enExample)
AU (1) AU2011282549A1 (enExample)
BR (1) BR112013002319A2 (enExample)
CA (1) CA2806982A1 (enExample)
CL (1) CL2013000308A1 (enExample)
CO (1) CO6680670A2 (enExample)
MX (1) MX2013001227A (enExample)
NZ (1) NZ607306A (enExample)
PH (1) PH12013500205A1 (enExample)
RU (1) RU2013108394A (enExample)
SG (1) SG187653A1 (enExample)
TW (1) TW201210601A (enExample)
WO (1) WO2012016109A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697458B2 (en) 2009-04-22 2014-04-15 Shat-R-Shield, Inc. Silicone coated light-emitting diode
US8889123B2 (en) * 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) * 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) * 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8900571B2 (en) * 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8741281B2 (en) * 2010-08-19 2014-06-03 Allergan, Inc. Compositions and soft tissue replacement methods
US8926963B2 (en) * 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
WO2012024072A1 (en) * 2010-08-19 2012-02-23 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
US9005605B2 (en) * 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) * 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
JP2015537028A (ja) * 2012-11-16 2015-12-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 皮膚修復のための組成物および方法
CA2890034A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
ES2730895T3 (es) * 2013-09-27 2019-11-13 Allergan Inc Compuestos y métodos para reparación cutánea
RU2625548C1 (ru) * 2015-04-29 2017-07-14 Жанна Юрьевна Юсова Способ коррекции возрастных изменений кожи лица
RU2663391C1 (ru) * 2018-01-30 2018-08-03 Игорь Николаевич Бондаренко Способ эстетической коррекции мягких тканей лица

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
WO2000015608A1 (fr) * 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. Derives e de phenyl-prostaglandine a substitution-φ et medicaments les contenant comme ingredient actif
JP4618548B2 (ja) * 1999-11-24 2011-01-26 小野薬品工業株式会社 骨量低下疾患治療剤
KR100826866B1 (ko) * 2001-07-23 2008-05-06 오노 야꾸힝 고교 가부시키가이샤 Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하질환의 치료제
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
WO2004032965A1 (ja) * 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. 内因性修復因子産生促進剤
US6875787B2 (en) 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
AU2004211936B2 (en) * 2003-02-11 2008-09-11 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
JPWO2006016695A1 (ja) * 2004-08-10 2008-05-01 小野薬品工業株式会社 Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
JP2006321737A (ja) * 2005-05-18 2006-11-30 Ono Pharmaceut Co Ltd Ｅｐ４アゴニストを含有する神経変性疾患の予防、治療および／または進展抑制剤
JP2007023028A (ja) * 2005-06-16 2007-02-01 Ono Pharmaceut Co Ltd 内耳疾患治療剤
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
BRPI0720254A2 (pt) * 2006-12-15 2014-01-07 Glaxo Group Ltd Derivados de benzamida como agonistas do receptor ep4
US20100081631A1 (en) * 2006-12-18 2010-04-01 Guang Liang Jiang Methods and compositions for treating gastrointenstial disorders
US8507545B2 (en) * 2007-05-08 2013-08-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical

Also Published As

Publication number Publication date
CA2806982A1 (en) 2012-02-02
RU2013108394A (ru) 2014-09-10
TW201210601A (en) 2012-03-16
WO2012016109A2 (en) 2012-02-02
EP2598140A2 (en) 2013-06-05
CN103068382A (zh) 2013-04-24
EP2598140B1 (en) 2015-01-14
AU2011282549A1 (en) 2013-02-28
MX2013001227A (es) 2013-04-24
CO6680670A2 (es) 2013-05-31
PH12013500205A1 (en) 2017-08-23
CL2013000308A1 (es) 2013-04-12
BR112013002319A2 (pt) 2016-05-24
KR20130130694A (ko) 2013-12-02
US20120136011A1 (en) 2012-05-31
JP2013536183A (ja) 2013-09-19
WO2012016109A3 (en) 2012-03-22
NZ607306A (en) 2015-03-27
SG187653A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
AR082428A1 (es) Uso de un compuesto agonista de ep4 para preparar una composicion farmaceutica util para tratar una imperfeccion de la piel y metodos para reparar la piel relacionados
CO2020004249A2 (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
AR084144A1 (es) Compuestos y metodos para restaurar la piel
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
ECSP17085494A (es) Piridinas sustituidas y método de uso
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
CO6680699A2 (es) Derivados de amina para el control de plagas
BR112015017997A8 (pt) amidas de quinolina e quinoxalina como moduladores de canais de sódio, composição farmacêutica que as compreende e uso
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
MX2015011955A (es) Lipidos y composiciones de lipidos para el suministro de agentes activos.
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
BR112015024530A8 (pt) compostos derivados de naftiridina úteis como antagonistas de integrina alfa-v-beta-6, composição farmacêutica, e, uso de um composto
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
MX2015014336A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
UY38065A (es) Nuevas antranilamidas, su uso como insecticida y procesos para su preparación
MX383928B (es) Derivado de piridona que tiene un grupo tetrahidropiranilmetilo.
NI201500050A (es) Benzamidas
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
EA201391524A1 (ru) Производные гликозида и их применение
EA201591259A1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
MX2013010308A (es) 2,4-pirimidindiaminas sustituidas para uso en lupus discoide.

Legal Events

Date Code Title Description
FB Suspension of granting procedure